SCHEMBL12306194

SCHEMBL12306194

COc1ccc(-c2cc(-c3ccc(-c4ccc(-c5ccccc5)cc4)cc3)nc(-c3ccccc3)n2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.66
ACACA Q13085 1/20 0.62
ADORA3 P0DMS8 2/20 0.59
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
MAPT P10636 3/20 0.59
TSHR P16473 1/20 0.59
ATM Q13315 1/20 0.59
KDM4E B2RXH2 4/20 0.58
ALDH1A1 P00352 3/20 0.58
HPGD P15428 2/20 0.58
LMNA P02545 2/20 0.58
ENPP3 O14638 1/20 0.58
ENPP1 P22413 1/20 0.58
HTT P42858 1/20 0.58
NTSR1 P30989 1/20 0.58
S1PR1 P21453 1/20 0.57
NR1H4 Q96RI1 1/20 0.57
MAOA P21397 1/20 0.56
MAOB P27338 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12306219 1.00 BRD4 (0.66) BRD4ACACAADORA3MEN1KMT2A
SCHEMBL12306199 1.00 BRD4 (0.66) BRD4ACACAADORA3MEN1KMT2A
SCHEMBL12306214 1.00 BRD4 (0.66) BRD4ACACAADORA3MEN1KMT2A
SCHEMBL29573423 0.98 BRD4 (0.68) BRD4ACACAADORA3MEN1KMT2A
SCHEMBL28067056 0.98 BRD4 (0.68) BRD4ACACAADORA3MEN1KMT2A
SCHEMBL12306180 0.98 BRD4 (0.68) BRD4ACACAADORA3MEN1KMT2A
SCHEMBL12306221 0.93 ADORA3 (0.59) BRD4ACACAADORA3MEN1KMT2A
SCHEMBL14307273 0.92 BRD4 (0.65) BRD4ACACAADORA3MEN1KMT2A
SCHEMBL14307275 0.90 BRD4 (0.60) BRD4ACACAADORA3MEN1KMT2A
SCHEMBL12306193 0.90 BRD4 (0.60) BRD4ACACAADORA3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220216422-A1 Electroluminescent Device UDC IRELAND LTD (IE) 2022-07-07 US disclosed
US-9923148-B2 Electroluminescent device UDC IRELAND LIMITED (IE) 2018-03-20 US disclosed
US-9923148-B2 Electroluminescent device UDC IRELAND LIMITED (IE) 2018-03-20 US disclosed
US-20170194568-A9 Electroluminescent Device UDC IRELAND LIMITED (IE) 2017-07-06 US disclosed
US-20170194568-A9 Electroluminescent Device UDC IRELAND LIMITED (IE) 2017-07-06 US disclosed
US-20130079517-A1 Electroluminescent Device BASF SE (DE) 2013-03-28 US disclosed
US-20130079517-A1 Electroluminescent Device BASF SE (DE) 2013-03-28 US disclosed
US-8012602-B2 Blue emitting, durable, organoelectroluminescent layers containing pyrimidine moieties; full color displays; light emission efficiency and brightness BASF SE (DE) 2011-09-06 US disclosed
US-8012602-B2 Blue emitting, durable, organoelectroluminescent layers containing pyrimidine moieties; full color displays; light emission efficiency and brightness BASF SE (DE) 2011-09-06 US disclosed
US-20100240892-A1 ELECTROLUMINESCENT DEVICE SCHAEFER THOMAS 2010-09-23 US disclosed
US-20100240892-A1 ELECTROLUMINESCENT DEVICE SCHAEFER THOMAS 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220216422-A1 Electroluminescent Device PNPO, ODC1, AXL BRD4 1471/4885ACACA 1993/4885ADORA3 617/4885
US-20170194568-A9 Electroluminescent Device DPYD, PNPO, TYMP BRD4 691/4885ACACA 2133/4885ADORA3 515/4885
US-20130079517-A1 Electroluminescent Device DPYD, PNPO, TYMP BRD4 691/4885ACACA 2133/4885ADORA3 515/4885
US-20100240892-A1 ELECTROLUMINESCENT DEVICE PNPO, ODC1, AXL BRD4 1471/4885ACACA 1993/4885ADORA3 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.